Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08PFA
|
||||
| Former ID |
DIB016579
|
||||
| Drug Name |
Rivoglitazone
|
||||
| Synonyms |
CS-011; DE-101; Rivoglitazone (ophthalmic); Rivoglitazone (ophthalmic), Santen; CS-011 (ophthalmic), Santen
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Ocular inflammation [ICD9: 370.33; ICD10:H16.229] | Phase 3 | [522181] | ||
| Company |
Sankyo Co Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H19N3O4S
|
||||
| Canonical SMILES |
N1C(=O)SC(C1=O)Cc1ccc(OCc2n(c3c(n2)ccc(c3)OC)C)cc1
|
||||
| CAS Number |
CAS 185428-18-6
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Peroxisome proliferator activated receptor gamma | Target Info | Agonist | [531434] | |
| PANTHER Pathway | CCKR signaling map ST | ||||
| WikiPathways | Wnt Signaling Pathway Netpath | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Differentiation of white and brown adipocyte | |||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| Adipogenesis | |||||
| SREBP signalling | |||||
| Nuclear Receptors | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.